Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.97 CAD
Market Cap: 127.4m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Intrinsic Value

ARCH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ARCH stock under the Base Case scenario is 0.29 CAD. Compared to the current market price of 1.97 CAD, Arch Biopartners Inc is Overvalued by 85%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ARCH Intrinsic Value
0.29 CAD
Overvaluation 85%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arch Biopartners Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ARCH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ARCH?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Arch Biopartners Inc

Provide an overview of the primary business activities
of Arch Biopartners Inc.

What unique competitive advantages
does Arch Biopartners Inc hold over its rivals?

What risks and challenges
does Arch Biopartners Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Arch Biopartners Inc.

Provide P/S
for Arch Biopartners Inc.

Provide P/E
for Arch Biopartners Inc.

Provide P/OCF
for Arch Biopartners Inc.

Provide P/FCFE
for Arch Biopartners Inc.

Provide P/B
for Arch Biopartners Inc.

Provide EV/S
for Arch Biopartners Inc.

Provide EV/GP
for Arch Biopartners Inc.

Provide EV/EBITDA
for Arch Biopartners Inc.

Provide EV/EBIT
for Arch Biopartners Inc.

Provide EV/OCF
for Arch Biopartners Inc.

Provide EV/FCFF
for Arch Biopartners Inc.

Provide EV/IC
for Arch Biopartners Inc.

Show me price targets
for Arch Biopartners Inc made by professional analysts.

What are the Revenue projections
for Arch Biopartners Inc?

How accurate were the past Revenue estimates
for Arch Biopartners Inc?

What are the Net Income projections
for Arch Biopartners Inc?

How accurate were the past Net Income estimates
for Arch Biopartners Inc?

What are the EPS projections
for Arch Biopartners Inc?

How accurate were the past EPS estimates
for Arch Biopartners Inc?

What are the EBIT projections
for Arch Biopartners Inc?

How accurate were the past EBIT estimates
for Arch Biopartners Inc?

Compare the revenue forecasts
for Arch Biopartners Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Arch Biopartners Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Arch Biopartners Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Arch Biopartners Inc compared to its peers.

Compare the P/E ratios
of Arch Biopartners Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Arch Biopartners Inc with its peers.

Analyze the financial leverage
of Arch Biopartners Inc compared to its main competitors.

Show all profitability ratios
for Arch Biopartners Inc.

Provide ROE
for Arch Biopartners Inc.

Provide ROA
for Arch Biopartners Inc.

Provide ROIC
for Arch Biopartners Inc.

Provide ROCE
for Arch Biopartners Inc.

Provide Gross Margin
for Arch Biopartners Inc.

Provide Operating Margin
for Arch Biopartners Inc.

Provide Net Margin
for Arch Biopartners Inc.

Provide FCF Margin
for Arch Biopartners Inc.

Show all solvency ratios
for Arch Biopartners Inc.

Provide D/E Ratio
for Arch Biopartners Inc.

Provide D/A Ratio
for Arch Biopartners Inc.

Provide Interest Coverage Ratio
for Arch Biopartners Inc.

Provide Altman Z-Score Ratio
for Arch Biopartners Inc.

Provide Quick Ratio
for Arch Biopartners Inc.

Provide Current Ratio
for Arch Biopartners Inc.

Provide Cash Ratio
for Arch Biopartners Inc.

What is the historical Revenue growth
over the last 5 years for Arch Biopartners Inc?

What is the historical Net Income growth
over the last 5 years for Arch Biopartners Inc?

What is the current Free Cash Flow
of Arch Biopartners Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Arch Biopartners Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Arch Biopartners Inc

Current Assets 1.5m
Cash & Short-Term Investments 44k
Receivables 1.5m
Other Current Assets 32.2k
Current Liabilities 7.6m
Accounts Payable 2.7m
Accrued Liabilities 116.4k
Short-Term Debt 2.2m
Other Current Liabilities 2.6m
Non-Current Liabilities 500k
Long-Term Debt 500k
Efficiency

Earnings Waterfall
Arch Biopartners Inc

Revenue
4.5m CAD
Operating Expenses
-10m CAD
Operating Income
-5.5m CAD
Other Expenses
-620.6k CAD
Net Income
-6.1m CAD

Free Cash Flow Analysis
Arch Biopartners Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ARCH Profitability Score
Profitability Due Diligence

Arch Biopartners Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Year Average ROIC
Exceptional ROE
Exceptional ROIC
65/100
Profitability
Score

Arch Biopartners Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

ARCH Solvency Score
Solvency Due Diligence

Arch Biopartners Inc's solvency score is 16/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
16/100
Solvency
Score

Arch Biopartners Inc's solvency score is 16/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARCH Price Targets Summary
Arch Biopartners Inc

Wall Street analysts forecast ARCH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARCH is 3.57 CAD with a low forecast of 3.54 CAD and a high forecast of 3.68 CAD.

Lowest
Price Target
3.54 CAD
79% Upside
Average
Price Target
3.57 CAD
81% Upside
Highest
Price Target
3.68 CAD
87% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ARCH?

Click here to dive deeper.

Dividends

Arch Biopartners Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ARCH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Arch Biopartners Inc Logo
Arch Biopartners Inc

Country

Canada

Industry

Life Sciences Tools & Services

Market Cap

126.6m CAD

Dividend Yield

0%

Description

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

Contact

ONTARIO
TORONTO
545 King St W
+16474287031.0
archbiopartners.com

IPO

1996-10-09

Employees

-

Officers

Co-Founder, CEO, President & Director
Mr. Richard Gabriel Muruve
Co-Founder, Chief Science Officer & Member of Scientific Advisory Board
Dr. Daniel Abraham Muruve M.D.
CFO & Director
Mr. Andrew Bishop CFA
Co-Founder & Principal Scientist
Dr. Paul Beck
Director of Communications
Mr. Aaron Benson

See Also

Discover More
What is the Intrinsic Value of one ARCH stock?

The intrinsic value of one ARCH stock under the Base Case scenario is 0.29 CAD.

Is ARCH stock undervalued or overvalued?

Compared to the current market price of 1.97 CAD, Arch Biopartners Inc is Overvalued by 85%.

Back to Top